Arcus Biosciences, Inc. (RCUS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arcus Biosciences, Inc. (RCUS) Healthcare & Pipeline Overview

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing cancer therapies, featuring a robust pipeline of innovative treatments and strategic partnerships aimed at improving patient outcomes in oncology.

What Is the Investment Thesis for RCUS?

Arcus Biosciences, Inc. presents a compelling investment thesis driven by its robust pipeline and strategic collaborations. The company’s lead candidates, Etrumadenant and Zimberelimab, are positioned in lucrative markets with significant unmet needs in oncology, particularly in non-small cell lung cancer and pancreatic cancer. With a market cap of $3.71B and a gross margin of 97%, Arcus demonstrates strong financial health despite a current profit margin of -156.4%. The ongoing Phase 1b/2 and Phase 2 trials for its key therapies are expected to provide critical data points that could enhance the company's market position and attract further investment. Additionally, the collaboration with AstraZeneca for Domvanalimab in a Phase 3 trial represents a potential catalyst for future revenue streams. However, investors should remain aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including trial outcomes and regulatory approvals, which could impact the company's growth trajectory.

Based on FMP financials and quantitative analysis

RCUS Key Highlights

Market cap of $3.71B indicates strong investor interest and potential for growth in the biopharmaceutical sector.

• Gross margin of 97% highlights the company's ability to maintain high profitability on its products, despite current operational losses.
• Robust pipeline with multiple candidates in various stages of clinical trials, including Etrumadenant and Zimberelimab.
• Strategic partnerships with industry leaders such as AstraZeneca and Strata Oncology enhance research capabilities and market access.
• Employee base of 627 reflects the company's commitment to expanding its operational capacity and expertise in oncology.

Who Are RCUS's Competitors?

RCUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RCUS's Key Strengths?

Strong pipeline with multiple candidates in advanced clinical stages.

• High gross margin indicating strong potential profitability.
• Strategic collaborations with established pharmaceutical companies.
• Experienced leadership team with a proven track record in biopharmaceuticals.

What Are RCUS's Weaknesses?

Current negative profit margin due to high R&D expenses.

• Dependence on successful clinical trial outcomes for future growth.
• Limited revenue streams as the company has not yet commercialized products.
• Market volatility affecting investor sentiment and stock performance.

What Could Drive RCUS Stock Higher?

Results from Phase 1b/2 clinical trials for Etrumadenant expected in 2026.

• Phase 1b clinical trials for Zimberelimab are currently underway.
• Phase 3 clinical trial results for Domvanalimab in collaboration with AstraZeneca anticipated in late 2026.
• Development of Quemliclustat in Phase 1/1b studies for metastatic pancreatic cancer.
• Progression of AB521 in Phase 1 studies for von Hippel-Lindau disease.

What Are the Key Risks for RCUS?

Financial-distress signal — its Altman Z-Score of 1.58 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-88.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Regulatory approval risks associated with clinical trials and product commercialization.
• Financial risks due to high R&D expenditures and current negative profit margins.
• Market competition from other biotechnology firms developing similar therapies.
• Dependency on successful trial outcomes for future growth and revenue generation.

What Are the Growth Opportunities for RCUS?

• Growth opportunity 1: Arcus's lead candidate, Etrumadenant, targets the A2a/A2b adenosine receptors, which play a crucial role in immune suppression in tumors. The global market for adenosine receptor antagonists is expected to grow significantly, driven by increasing research and development in immuno-oncology. With Etrumadenant currently in Phase 1b/2 trials, successful outcomes could position Arcus as a leader in this emerging market segment within the next 2-3 years.
• Growth opportunity 2: Zimberelimab, an anti-PD-1 antibody, is in Phase 1b clinical trials and represents a significant growth opportunity in the immunotherapy space. As Zimberelimab progresses through clinical trials, positive results could lead to accelerated approval pathways, enhancing Arcus's market presence and revenue potential.
• Growth opportunity 3: The collaboration with AstraZeneca for Domvanalimab in a Phase 3 trial for unresectable Stage III non-small cell lung cancer presents a substantial opportunity. The non-small cell lung cancer market is expected to exceed $30 billion by 2026, and successful trial results could lead to a strong partnership, expanding Arcus's product offerings and market reach significantly.
• Growth opportunity 4: The development of Quemliclustat, a small-molecule CD73 inhibitor, is currently in Phase 1/1b studies for first-line metastatic pancreatic cancer. Given the high unmet need in pancreatic cancer treatment, with a market projected to grow to $5 billion by 2027, Arcus could capture significant market share if clinical trials demonstrate efficacy.
• Growth opportunity 5: AB521, an oral HIF-2a inhibitor in Phase 1 trials for von Hippel-Lindau disease, addresses a rare but serious genetic condition. The market for rare disease therapies is rapidly expanding, with potential revenues reaching billions. Successful development and commercialization of AB521 could position Arcus favorably within this niche market.

What Opportunities Does RCUS Have?

• Growing global market for cancer therapeutics with increasing demand for innovative treatments.
• Potential for accelerated regulatory approvals for key drug candidates.
• Expansion of collaborations and partnerships to enhance product pipeline.
• Rising prevalence of cancer driving the need for effective therapies.

What Threats Does RCUS Face?

• Intense competition from established and emerging biopharmaceutical companies.
• Regulatory hurdles and delays in clinical trial approvals.
• Market risks associated with the volatility of biotechnology stocks.
• Potential for negative trial results impacting stock performance and investor confidence.

What Are RCUS's Competitive Advantages?

• Strong pipeline of innovative drug candidates targeting critical areas in oncology.
• Strategic partnerships with industry leaders enhance research capabilities and market access.
• Expertise in developing targeted therapies provides a competitive advantage in a crowded market.
• Focus on unmet medical needs in oncology positions the company favorably for future growth.
• Robust intellectual property portfolio protecting its innovative therapies.

What Does RCUS Do?

Founded in 2015 and headquartered in Hayward, California, Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that specializes in developing and commercializing innovative therapies for cancer treatment. The company was established with the mission to transform cancer care through the development of novel therapies that target specific mechanisms of tumor growth and immune evasion. Arcus has built a diverse pipeline of drug candidates, including Etrumadenant, a dual A2a/A2b adenosine receptor antagonist currently in Phase 1b/2 clinical trials, and Zimberelimab, an anti-PD-1 antibody also in Phase 1b clinical trials for monotherapy. Additionally, the company is advancing Domvanalimab, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer, in combination with Zimberelimab. Other notable candidates include Quemliclustat, a small-molecule CD73 inhibitor in Phase 1/1b studies for first-line metastatic pancreatic cancer, and AB521, an oral HIF-2a inhibitor in Phase 1 trials for von Hippel-Lindau disease. Arcus has established collaborations with key industry players, including a clinical development agreement with Strata Oncology, Inc. for Zimberelimab and partnerships with AstraZeneca and BVF Partners L.P. for Domvanalimab in a registrational Phase 3 clinical trial. The company has also entered into license agreements with Taiho Pharmaceutical Co., Ltd., Abmuno Therapeutics LLC, and WuXi Biologics for the development of anti-CD39 antibodies targeting cancer. Through its innovative approach and strategic collaborations, Arcus aims to enhance the treatment landscape for cancer patients and address significant unmet medical needs in oncology.

What Products and Services Does RCUS Offer?

• Develops innovative cancer therapies targeting specific tumor mechanisms.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Collaborates with leading pharmaceutical companies to enhance research and development efforts.
• Focuses on unmet medical needs in oncology through targeted therapies.
• Engages in licensing agreements to expand its product pipeline.
• Aims to commercialize successful therapies for cancer treatment in the United States.

How Does RCUS Make Money?

• Generates revenue through the development and commercialization of cancer therapies.
• Engages in strategic collaborations with other pharmaceutical companies to share research costs and risks.
• Pursues licensing agreements for its drug candidates to enhance market reach.
• Invests in clinical trials to validate the efficacy of its products, aiming for regulatory approvals.
• Plans to monetize successful therapies through direct sales and partnerships.

What Industry Does RCUS Operate In?

The biotechnology industry, particularly in oncology, is experiencing rapid growth driven by advancements in personalized medicine and immunotherapy. The global cancer therapeutics market is projected to reach approximately $250 billion by 2026, fueled by increasing cancer prevalence and demand for innovative treatment options. Arcus Biosciences, Inc. is well-positioned within this landscape, focusing on novel therapies that target specific tumor mechanisms. The competitive landscape includes notable peers such as ImmunityBio, Inc. (IBRX), Cogent Biosciences, Inc. (COGT), and Beam Therapeutics Inc. (BEAM), each vying for market share in the lucrative oncology sector. Arcus's innovative pipeline and strategic collaborations provide a competitive edge in addressing unmet medical needs in cancer treatment.

Who Are RCUS's Key Customers?

• Oncology healthcare providers and hospitals seeking innovative cancer treatments.
• Pharmaceutical companies interested in collaboration for drug development.
• Patients with cancer in need of novel therapeutic options.
• Investors looking for opportunities in the biopharmaceutical sector.
• Research institutions engaged in oncology studies and trials.

Wall Street analysts project Arcus Biosciences, Inc. revenue of about $72.1M for fiscal 2026, with EPS near $-3.67. The estimate reflects 9 contributing analysts.

Quarterly Financial Performance: Arcus Biosciences, Inc.

Revenue for Arcus Biosciences, Inc. came in at $41.0M during Q2 2026, a 141.2% improvement versus the preceding quarter. The company recorded a net loss of $91.0M, with diluted EPS of $-0.72. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, RCUS averaged $-0.98 in diluted EPS.

RCUS Valuation & Market Position

With a $3.71B market cap, Arcus Biosciences, Inc. sits in the mid-cap segment of the market. Relative to its peer group, RCUS's quantitative score of 19/100 is below the peer average of 76/100.

Return on equity for Arcus Biosciences, Inc. stands at -88.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.4%, the inverse of the P/E and a quick read on earnings relative to price.

Arcus Biosciences, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.58 places it in the distress zone, a signal of elevated financial risk.

Arcus Biosciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 16.6% above estimates on average.

Company Profile

Arcus Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hayward, US. The company is led by CEO Terry J. Rosen. RCUS has traded publicly since 2018.

RCUS Financials

RCUS Latest News

RCUS Analyst Consensus

RCUS MoonshotScore

Arcus Biosciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources